Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer

Parayath, Neha N.; Gandham, Srujan; Leslie, Fraser; Amiji, Mansoor M.

doi:10.1016/j.canlet.2019.07.002

Cited by 52 publications

(35 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Editing M2 phenotype repolarize to M1 is a promising strategy for cancer therapy. For instance, intraperitoneal paclitaxel in combination with MicroRNA-125b can consolidate the anti-tumor efficacy of paclitaxel as seen by impeding formation of ascites and cut down VEGF levels 159. In mouse models of several adenocarcinomas, like colon cancer, breast cancer and sarcoma, CSF-1R antibody antagonists combined with CD40 agonistic antibody drive repolarization from M2 to a tumoricidal phenotype and prolong survival 160.…”

Section: Resultsmentioning

confidence: 99%

Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis

Yin¹,

Shen²,

Yu³

et al. 2019

OTT

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) that appear in every stage of cancer progression are usually tumor-promoting cells and are present abundantly in the tumor-associated microenvironment. In ovarian cancer, the overall and intratumoral M1/M2 ratio is a relatively efficient TAM parameter for predicting the prognosis of patients, especially for serous tissue type cancer. TAMs exhibit immunological checkpoint modulators, such as the B7 family and programmed death-ligand 1 (PD-L1), and play a key role in the development, metastasis and invasion of ovarian cancer, but the underlying mechanism is barely understood. Ovarian cancer is a severe gynecological malignancy with high mortality. Ovarian cancer-associated death can primarily be attributed to cancer metastasis. The majority of patients are diagnosed with wide dissemination in the peritoneum and omentum, limiting the effectiveness of surgery and chemotherapy. In addition, unlike other well-documented cancers, metastasis through vasculature is not a usual dissemination pathway in ovarian cancer. This review sheds light on TAMs and the main process and mechanism of ovarian cancer metastasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis

Yin¹,

Shen²,

Yu³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…Indeed it may be an approach to suppress debris-stimulated ovarian tumor growth by preventing the therapy-induced surge of cytokines and lipid mediators (236). Hyaluronic acid-based nanoparticles encapsulating miR-125b (HA-PEI-miR-125b) specifically target TAMs in the peritoneal cavity of a syngeneic ID8-VEGF ovarian cancer mouse model and repolarize macrophages to an immuneactivating phenotype (increased CD80 and iNOS and reduced CD206 and ARG1 expression) (237). Intraperitoneal administration of paclitaxel in combination with HA-PEI-miR-125b nanoparticles enhanced the antitumor efficacy of paclitaxel mediating by the significant reduction in the ascite fluid and peritoneal VEGF levels (237).…”

Section: Tams and Ovarian Cancer Treatmentmentioning

confidence: 99%

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

et al. 2020

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are major innate immune cells that constitute up to 50% of the cell mass of human tumors. TAMs are highly heterogeneous cells that originate from resident tissue-specific macrophages and from newly recruited monocytes. TAMs' variability strongly depends on cancer type, stage, and intratumor heterogeneity. Majority of TAMs are programmed by tumor microenvironment to support primary tumor growth and metastatic spread. However, TAMs can also restrict tumor growth and metastasis. In this review, we summarized the knowledge about the role of TAMs in tumor growth, metastasis and in the response to cancer therapy in patients with five aggressive types of cancer: breast, colorectal, lung, ovarian, and prostate cancers that are frequently metastasize into distant organs resulting in high mortality of the patients. Two major TAM parameters are applied for the evaluation of TAM correlation with the cancer progression: total amount of TAMs and specific phenotype of TAMs identified by functional biomarkers. We summarized the data generated in the wide range of international patient cohorts on the correlation of TAMs with clinical and pathological parameters of tumor progression including lymphatic and hematogenous metastasis, recurrence, survival, therapy efficiency. We described currently available biomarkers for TAMs that can be measured in patients' samples (tumor tissue and blood). CD68 is the major biomarker for the quantification of total TAM amounts, while transmembrane receptors (stabilin-1, CD163, CD206, CD204, MARCO) and secreted chitinase-like proteins (YKL-39, YKL-40) are used as biomarkers for the functional TAM polarization. We also considered that specific role of TAMs in tumor progression can depend on the localization in the intratumoral compartments. We have made the conclusion for the role of TAMs in primary tumor growth, metastasis, and therapy sensitivity for breast, colorectal, lung, ovarian, and prostate cancers. In contrast to other cancer types, majority of clinical studies indicate that TAMs in colorectal cancer have protective role for the patient and interfere with primary tumor growth

show abstract

“…Nanoparticles combined with paclitaxel enhanced anti-ovarian cancer efficacy compared to that with pacitaxel alone. 90 Nanoparticles encapsulating miR-125b also successfully reprogrammed TAMs to the M1 phenotype in non-small-cell lung cancer (NSCLC), which may play an important role in immunotherapy. 91…”

Section: Mir-125b Controls Drug Resistance In Cancermentioning

confidence: 99%

The Emerging Roles of miR-125b in Cancers

Wang¹,

Zeng²,

Jiang³

2020

CMAR

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are endogenous, noncoding, single-stranded RNA molecules of 22 nucleotides in length. MiRNAs have both tumor-suppressive properties and oncogenic properties that can control critical processes in tumors. Mature miR-125b originates from miR-125b-1 and miR-125b-2 and leads to the degradation of target mRNAs or the inhibition of translation through binding to the 3′ untranslated regions (3′-UTR) of target mRNAs. Importantly, miR-125b is involved in regulating NF-κB, p53, PI3K/Akt/mTOR, ErbB2, Wnt, and another signaling pathways, thereby controlling cell proliferation, differentiation, metabolism, apoptosis, drug resistance and tumor immunity. This review aims to summarize the recent literature on the role of miR-125b in the regulation of tumorigenesis and to explore its potential clinical application in the diagnosis, prognosis and clinical treatment of tumors.

show abstract

Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer

Cited by 52 publications

References 40 publications

<p>Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis</p>

<p>Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis</p>

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

<p>The Emerging Roles of miR-125b in Cancers</p>

Contact Info

Product

Resources

About